High Purity Rimonabant Weight Loss Powders Rimonabant Hydrochloride CAS 158681-13-1
- Fabricant: Dewael
- Essai de produit: 99%+
- Apparence:Poudre cristalline blanche.
- Lieu d'origine: Chine
- certificat: SGS,ISO9001, GMP
- Quantité minimum d'achat: 10g
- Détails de l'' emballage: 1 kg/sac en aluminium,25kg/drum or as your requirements
- Heure de livraison: Dans 12 heures après réception de votre paiement
- Modalités de paiement: Western union, MoneyGram,Bitcoin,Virement
- livraison: EMS,DHL,Fedex,UPS,TNT et ainsi de suite.
- Politique: Re-Politique de livraison
- Capacité d'approvisionnement: 500-600kg/mois
High Purity Rimonabant Weight Loss Powders Rimonabant Hydrochloride CAS 158681-13-1
Détails:
Rimonabant hydrochloride
Nom du produit: Rimonabant hydrochloride
Synonymes: RIMONABANT HYDROCHLORIDE;5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-n-1-piperidinyl-1h-pyrazole-3-carboxamide monohydrochloride;ACOMPLIA;ACOMPLIA (RIMONABANT;RIMONABANT HCL;Rimonabant(Acomplia);RimonabantConsultedStandard;Acomplia, SR141716
CAS: 158681-13-1
MF: C22H21Cl3N4O.ClH
MW: 500.25
Chemical Properties White to Off-White Crystalline Solid
Usage The first of a new class of selective (Cannabinoid-1 (CB-1) receptor antagonists
Usage A brain cannabinoid receptor (CB1) antagonist. Antiobesity agent.
COA:
|
Nom du produit
|
Rimonabant
|
|||
|
CAS No.
|
168273-06-1 |
Outer Packing
|
1kg/bag | |
|
Production date
|
May 14th. 2018 |
Durée de conservation
|
May 13th. 2020 | |
|
Products Standard
|
norme d'entreprise | |||
|
Items of analysis
|
spécification
|
Résultats
|
||
| Assay by (HPLC) | 99%-101% | 99.43% | ||
| Characters/appearance | White to off White powder | Conforme | ||
| Odor and taste | Odorless | Conforme | ||
| Identification | Positive reaction | Conforme | ||
| Mesh size/sieve analysis | 100% pass 80 mesh | Conforme | ||
| Perte au séchage | 1% Max | 0.78% | ||
| Water | ≤2.0% | 0.1% | ||
| Résidus au feu | 01%Max | Conforme | ||
| Single impurity | 0.1% Max | Conforme | ||
| Malting point | 272.25 ºC | Conforme | ||
| Bolling point | 627 .69 ºC | Conforme | ||
| Refractive Index | N20O1.67 | Conforme | ||
| PH | 50-7.0 | 6.5 | ||
| pK Values | pK. 11.31(Predicted). pK„ 3. 22 (Predicted) | Conforme | ||
| Solubilité | Soluble in ethanol (-20 mg / ml). DMSO (25 mg / ml) .DMF (-20mg / ml). and water (< 1 mg / ml) | Conforme | ||
| Métaux lourds | NMT 10ppm | Conforme | ||
| Microbiological Control | 78cfu/g | 78cfu/g | ||
| Total Plate Count | 1000 cfu/g Max | Negative | ||
| Fungi | <100/g | Negative | ||
| Salmonella | Negative | Negative | ||
| Coll | negative | negative | ||
|
Conclusion
|
Qualified | |||
Rimonabant Description:
(1). Rimonabant hydrochloride (SR-141716A) is a potent and selective CB1 cannabinoid inverse agonist/antagonist with a Ki of 1.6 nM, minimal affinity for CB2, and and some GPR55 agonist activity. Rimonabant was developed as an anti-obesity drug because of its appetite suppressant activity, but was taken off the market because of side effects of depression and anxiety.
(2). Under development by Sanofi-Aventis, Acomplia (rimonabant) is a selective CB1 endocannabinoid receptor antagonist indicated for the treatment of obesity.
(3). It works by blocking endogenous cannabinoid binding to neuronal CB1 receptors. Activation of these receptors by endoegenous cannabinoids, such as anadamide, increases appetite. It is the most advanced endocannabinoid receptor antagonist in clinical development and offers a novel therapeutic approach to appetite control and weight reduction.
Rimonabant Applications:
(1). Rimonabant has a favorable safety profile and is generally well tolerated. Rimonabant is proving to be a very promising approach for managing two major and preventable risk factors for cardiovascular disease. This review summarizes the available evidence on the clinical efficacy and safety of rimonabant as a potential therapy for obesity and smoking cessation.
(2). Rimonabant hydrochloride also has potential as a treatment for smoking cessation because the endocannabinoid system is involved in the body’s response to tobacco dependence.
———————————————————————————————————————————————————————————————————————————————————————-
Contacter maintenant
Avis
Il n'y a pas encore de critiques.